Drug intelligence / Profile preview

NAV-005

Development stage: Preclinical
Lead developer: Navrogen
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

NAV-005 is a human IgG1 Fc fusion protein designed as a humoral immuno-oncology (HIO) factor antagonist. Developed by Navrogen, it specifically targets Mucin-16 (MUC16), also known as CA125, which is a tumor-produced protein that exerts immunosuppressive effects. By binding to CA125 with high affinity, NAV-005 blocks its interaction with SIGLEC receptors and therapeutic antibodies, thereby overcoming HIO factor-mediated resistance and restoring efficient humoral immune-mediated tumor cell killing. The drug is being developed for the treatment of various solid and hematologic malignancies, including lung, breast, colorectal, pancreatic cancers, lymphoma, and multiple myeloma.

Targets

MUC16 (Mucin-16)

Beyond the preview

Go deeper on NAV-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAV-005.

Explore the full profile